Labopharm warns of Phase III tramadol study

Labopharm says it will have to mount another trial of the pain drug tramadol if it can't gain FDA approval with existing data. The FDA has issued two approvable letters, noting that new data was needed. Regulators say that Labopharm's Phase III study of the once-daily therapy was flawed because its analysis failed to evaluate missing data from patients who had dropped out of the study.

- see this release for more
- read the AP report

Related Articles:
Labopharm IPO opens on an upbeat note. Report
Labopharm hit by another tramadol delay. Report
Labopharm shares sink on approvable letter. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.